Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Cash Flows

v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash Flows From Operating Activities    
Net income $ 24,575 $ 6,702
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 425 300
Interest accretion expense 34
Asset impairment - lab supplies 198
Amortization of deferred financing fees 58
Stock-based compensation 35 291
Amortization on operating lease right of use asset 396 448
Deferred taxes (21,254)
Change in fair value of note payable 110 547
Other changes in operating assets and liabilities:    
Accounts receivable 2,895 (3,466)
Other current assets (234) 73
Other long-term assets 1
Accounts payable (807) 120
Accrued salaries and bonus (321) 238
Accrued liabilities (273) (404)
Operating lease liabilities (382) (480)
Long-term liabilities 409 243
Net cash provided by operating activities 5,831 4,646
Cash Flows From Investing Activity    
Purchase of property and equipment (356) (876)
Net cash used in investing activities (356) (876)
Cash Flows From Financing Activities    
Payments made on note payable (4,400) (5,600)
Series C conversion costs (13) (161)
Cash paid for repurchase of restricted shares (18) (46)
Net cash used in financing activities (4,431) (5,807)
Net increase (decrease) in cash and cash equivalents 1,044 (2,037)
Cash and cash equivalents – beginning 1,461 3,498
Cash and cash equivalents – ending $ 2,505 $ 1,461